Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized opelconazole add-on therapy for refractory invasive pulmonary aspergillosis
2021-004554-32Phase 3Active
- Sponsor
- Pulmocide
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Invasive Aspergillosis and pulmonary aspergillosis comparing Opelconazole + systemic antifungal therapy with Placebo + systemic antifungal therapy (2 arms). Primary endpoint: Number of participants with complete or partial overall response. Started May 2022; status: active.
02
Drugs
opelconazole
03
Conditions
Acute Invasive Aspergillosispulmonary aspergillosis
Beyond the preview
Go deeper on 2021-004554-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004554-32.